Abstract:
ob<x>jective To analyze the short-term efficacy and safety of recombinant human growth hormone (rhGH), gonadotropin-releasing hormone analogue (GnRHa) alone and their combination in the treatment of early puberty children with idiopathic short stature (ISS).Methods From September 2017 to June 2019, 60 children with idiopathic short stature were randomly divided into three groups: group A (recombinant human growth hormone rhGH), group B (GnRHa) and group C (recombinant human growth hormone combined with gonadotropin-releasing hormone analogue). They were followed up every three months and supervised Height, weight, predicted final height (PAH), IGF-1, LH, FSH, E2 or T, uterus, ovary or testicle size, fasting blood glucose, thyroid function, liver function and other indicators were measured. Bone age was measured once every six months.Results After 1 half year follow-up, the height, bone age and predicted final height of the three groups were significantly different from those before treatment (P < 0.05), and the growth rate of the combined treatment group was higher than that of the single treatment group (P < 0.05). There was no significant difference in blood glucose, thyroid function and liver enzyme between the three groups (P > 0.05).Conclusion After rhGH and GnRHa alone and combined treatment, the height of children increased significantly, the effect of combined treatment group was better than that of single treatment group, and there was no significant adverse reaction in three groups before and after treatment.